Year None202420232022202120202019 Dec 16, 2024 Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for t Dec 06, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 03, 2024 Arcutis Announces Promotions on Executive Management Team Nov 13, 2024 Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour Nov 06, 2024 Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update Nov 04, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 24, 2024 Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Ato Oct 23, 2024 Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Confe Oct 18, 2024 Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Derm Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 1 - 9 of 56
